Open AccessS106: UBTF‐ATXN7L3 GENE FUSION DUE TO 17Q21.31 DELETION DEFINES NOVEL HIGH‐RISK ALL SUBTYPE AMENABLE TO MRD‐BASED TREATMENT INTENSIFICATION
Author(s) -
Bastian L.,
Hartmann A.,
Beder T.,
Hänzelmann S.,
Kässens J.,
Bultmann M.,
Höppner M. P.,
Franzenburg S.,
Wittig M.,
Franke A.,
Nagel I.,
Spielmann M.,
Reimer N.,
Busch H.,
Schwartz S.,
Steffen B.,
Viardot A.,
Döhner K.,
Kondakci M.,
Wulf G.,
Wendelin K.,
Renzelmann A.,
Kiani A.,
Trautmann H.,
Neumann M.,
Gökbuget N.,
Brüggemann M.,
Baldus C.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843320.74833.6a
Subject(s) - biology , fusion gene , minimal residual disease , genetics , bromodomain , epigenetics , gene , computational biology , transcriptome , exon , leukemia , gene expression